Immunization

The pneumococcal 13-valent conjugate vaccine (PCV13) was effective at preventing pneumococcal lower respiratory tract infection (LRTI) in older patients from Thailand.

Examining Trends From Past Respiratory Virus Seasons Can Inform New Vaccination Strategies

Investigators determined a series of risk factors that can lead to complicated pneumococcal bacteremia, including older age and key comorbidities.

New vaccine developments for Crimean-Congo hemorrhagic fever offer hope for prevention, highlighting pharmacists' crucial role in future vaccination efforts.

Post pandemic, invasive pneumococcal disease cases rise among youth due to declining vaccination rates, highlighting urgent public health concerns.

City-level COVID-19 vaccine mandates in the US have limited impact on vaccination rates and health outcomes.

CDC's recent statement raises concerns about vaccine safety and autism links, igniting debate among health experts and fueling vaccine hesitancy.

Measles resurges globally, threatening U.S. elimination status; pharmacists play a crucial role in vaccination efforts and outbreak response.

The SmartPhrase listed indications for PCV20 aligned with CDC guidelines and was incorporated into provider documentation, significantly improving vaccine uptake.

A series of predictors were associated with a higher likelihood of intensive care unit (ICU) admission and subsequently poor outcomes in patients with Streptococcus pneumoniae bacteremia.

A nasal vaccine against whooping cough shows promise in blocking infection and enhancing respiratory immunity, offering a needle-free solution.

Knowledge of serotype prevalence and virulence can optimize the management of community-acquired pneumonia.

Adults in the United States are often infected by serotypes of Streptococcus pneumoniae unique to the pneumococcal 21-valent conjugate vaccine (PCV21) compared with those unique to PCV20.

In children and adolescents, reinfection with COVID-19 increased the risk of worsened long COVID outcomes.

A groundbreaking vaccine shows 73% efficacy against Salmonella Paratyphi A, offering hope in combating enteric fever globally.

Low RSV vaccination rates among older adults in the US highlight missed opportunities for reducing hospitalizations and health care costs.

The 20-valent pneumococcal conjugate vaccine (PCV20) demonstrated higher vaccine effectiveness against invasive pneumococcal disease or all-cause pneumonia in cohorts of older adults.

Pharmacists play a vital role in vaccine education and administration.

COVID-19 mRNA vaccines enhance immune checkpoint inhibitor effectiveness in cancer therapy, significantly improving survival rates for patients with advanced tumors.

Influenza vaccination provided direct, non–infection-based benefits in older adults.

New research highlights the enhanced humoral response in lymphoma survivors receiving two doses of the PCV20 vaccine, emphasizing vaccination's critical role in infection prevention.

When administering T-cell–modifying therapies, infections during and after treatment are a serious and pertinent risk.